Australia's most trusted
source of pharma news
Sunday, 22 December 2024
Posted 8 April 2024 PM
Starpharma has launched a new UK-based company called Petalion Therapeutics with $38 million in backing from Medicxi and a former Boehringer Ingelheim executive at the helm.
Petalion will initially focus on developing novel targeted dendrimer-drug conjugate therapies in oncology, utilising Starpharma's proprietary DEP dendrimer platform technology.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.